AnalystBook Research · Company Intelligence

Cencora, Inc.

CORNYSE

Built from Cencora, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Cencora: Revenue grew 9.3% to $321.333B from $293.959B. Net income grew 3.0% to $1.554B from $1.509B. Free cash flow grew 7.0% to $3.207B from $2.998B. Operating margin expanded 8 bps to 0.82%. Cencora's annual comparison also shows capital spending grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue grew 9.3%OK
  • Profitability — Net income grew 3.0% to $1.554B from $1.509BOK
  • Cash flow — Free cash flow grew 7.0% to $3.207B from $2.998BOK
  • Margins — Operating margin expanded 8 bps to 0.82%OK
  • Accounting — Distress-range screen needs contextWatch
  • Insiders — 3 purchases and 14 salesOK

Business

Cencora sources and distributes pharmaceuticals and provides services across the human- and animal-health supply chains.

Where the revenue comes from

Fiscal 2025, as Cencora, Inc. reports it. History and quarterly detail are in the app.

  • U.S. Healthcare Solutions$291.0B
  • International Healthcare Solutions$30.4B

Leadership changes

From Cencora, Inc.'s own filings, the day they're filed.

  • James F. Cleary · Chief Financial Officer · departureeff. 2026-06-29
  • Ellen G. Cooper · Director · appointmenteff. 2026-01-20
  • D. Mark Durcan · Chairman · appointmenteff. 2025-10-01

Latest filings

  • 8-K · Company announcement2026-08-14
  • 8-K · Company announcement2026-08-12
  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-08-05
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Cencora, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full COR record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.